Our Milestones – so far.
Elastrin Therapeutics start development of tropoelastin mRNA, inlicensed from Tübingen University
Elastrin Therapeutics closes its second Seed Funding Round with Kizoo Technology Capital, Starbloom Capital and SC Launch (SCRA)
Elastrin Therapeutics closes its Seed Funding Round with Kizoo Technology Capital
Patent Application published for “Delivery Agents Targeted to Degraded Elastic Fibers”
Publication on targeted drug delivery to emphysematous lungs in Pulmonary Pharmacology & Therapeutics.
Patent application published for “Delivery Agents for Targeted Treatment of Elastin Degradation”
Publication on targeted EDTA chelation therapy in Journal of Controlled Release. Read it here.
NIH Director highlights the achievements and potential of the findings.
Patent awarded for “Elastin stabilization of connective tissue”
NIH Grant awarded for project “GAGs: Function &Fixation in Bioprosthetic Heart Valves” which supported Vyavahare’s research with over $5.8 million until 2011.
NIH Grant awarded for project “Calcification of Elastin -- Mechanisms and Prevention” which supported Vyavahare’s work in this field with over $2 million through 2008.